Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major obstructive sleep apnea markets reached a value of US$ 424.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 639.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.

The obstructive sleep apnea market has been comprehensively analyzed in IMARC's new report titled "Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obstructive sleep apnea refers to a sleep disorder characterized by repetitive interruptions in breathing during sleep. These interruptions, known as apneas, occur when the muscles in the throat fail to keep the airway open, resulting in partial or complete blockage of airflow. The obstruction can lead to a decrease in oxygen levels in the body, causing the patient to briefly wake up or experience shallow sleep in order to restore normal breathing. The most common symptoms associated with the ailment include loud snoring, excessive daytime sleepiness, gasping or choking during sleep, morning headaches, difficulty concentrating, irritability, restless sleep, etc. The diagnosis of the condition typically involves a thorough evaluation by a healthcare professional specializing in sleep disorders. It begins with a detailed assessment of the patient's medical history, symptoms, and risk factors. The healthcare provider may use questionnaires, such as the Epworth Sleepiness Scale, to assess daytime sleepiness. In many cases, a sleep study, either in a sleep laboratory or through a home-based sleep test, is conducted to confirm the diagnosis.

The rising cases of chronic nasal congestion due to allergies, sinus problems, nasal polyps, etc., which lead to partial or complete blockage of airflow, are primarily driving the obstructive sleep apnea market. Furthermore, the increasing prevalence of several associated risk factors, such as enlarged tonsils or adenoids, obesity, genetic predisposition, use of sedatives, smoking, etc., is also propelling the market growth. Besides this, the widespread adoption of uvulopalatopharyngoplasty for treating the ailment on account of its numerous benefits, including reduced apnea-hypopnea index, improved airflow, decreased cardiovascular risk, etc., is acting as another significant growth-inducing factor. Additionally, the inflating usage of mandibular advancement devices that are custom-made to fit the patient's mouth and work by repositioning the jaw to help keep the airway open during sleep is further bolstering the market growth. Apart from this, the escalating demand for hypoglossal nerve stimulation (HNS), which involves implanting a device to stimulate the hypoglossal nerve that controls tongue movement and other muscles involved in maintaining airway patency for improved breathing during sleep, is expected to drive the obstructive sleep apnea market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the obstructive sleep apnea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obstructive sleep apnea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obstructive sleep apnea market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obstructive sleep apnea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obstructive sleep apnea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current obstructive sleep apnea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the obstructive sleep apnea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the obstructive sleep apnea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the obstructive sleep apnea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of obstructive sleep apnea across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with obstructive sleep apnea across the seven major markets?
What is the size of the obstructive sleep apnea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of obstructive sleep apnea?
What will be the growth rate of patients across the seven major markets?

Obstructive Sleep Apnea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for obstructive sleep apnea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obstructive sleep apnea market?
What are the key regulatory events related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by status related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by phase related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by route of administration related to the obstructive sleep apnea market?